Understanding the potential for cytochrome P450 mediated drug-drug interactions is a critical step in the drug discovery process. While in vitro studies with CYP3A4, CYP2C9 and CYP2C19 have suggested the presence of multiple binding regions within the P450 active site based upon probe substrate-dependent inhibition profiles, similar studies have not been carried out with CYP2C8. The ability to understand CYP2C8 probe substrate sensitivity will enable appropriate in vitro and in vivo probe selection. In order to characterize the potential for probe substrate-dependent inhibition with CYP2C8, the inhibition potency of twenty-two known inhibitors of CYP2C8
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Introduction
The cytochrome P450 (P450) superfamily of drug metabolizing enzymes is involved in the metabolism of a majority of currently prescribed drugs and new chemical entities (Wienkers and Heath, 2005) . Within the P450 superfamily, CYP2C8 is responsible for 5-8% of P450-mediated metabolism and is involved in the metabolism of over 60 drugs, including antimalarials (amodiaquine), antidiabetics (pioglitazone, repaglinide and rosiglitazone), statins (cerivastatin and fluvastatin) and anticancer agents (paclitaxel) (Lai et al., 2009 ). Due to the general importance of CYP2C8 in drug clearance, assessment of probe substrate dependence on CYP2C8 inhibition is a key part of the drug discovery and development process . The overall goal of studying CYP2C8 probe substrate-dependent inhibition is to gain a comprehensive understanding of in vitro and in vivo sensitivity, which will enable appropriate probe substrate selection.
The in vitro marker reactions recommended by the U.S. Food and Drug Administration (FDA) guidance for measuring CYP2C8 inhibition include paclitaxel 6α-hydroxylation (preferred), as well as amodiaquine N-deethylation and rosiglitazone parahydroxylation (acceptable). Repaglinide and rosiglitazone are FDA recommended in vivo probe substrates for studying CYP2C8 inhibition (Huang et al., 2007) . No studies to our knowledge have compared the inhibition profiles of these probe substrates in vitro.
Our first aim was to measure the in vitro inhibition profiles of three clinically relevant CYP2C8 probe substrates (paclitaxel, repaglinide and rosiglitazone) and amodiaquine ( Figure 1 ) versus a panel of twenty-two known CYP2C8 inhibitors to determine the relative in vitro sensitivities of each probe substrate. In addition, the in vitro inactivation profiles for each probe substrate versus gemfibrozil 1-O-β-glucuronide, a known mechanism-based inactivator of CYP2C8 (Ogilvie et al., 2006) , were determined to evaluate the relative in vitro sensitivities towards irreversible inhibition.
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Montelukast, a leukotriene-receptor antagonist, is well characterized as a potent and selective inhibitor of CYP2C8 in vitro (Walsky et al., 2005) . In vitro phenotyping studies based on high montelukast concentrations (100-500 µM), indicated that montelukast 21-hydroxylation (M5 formation) is catalyzed by CYP3A and montelukast 36-hydroxylation (M6 formation) by CYP2C9. In vivo, montelukast undergoes oxidative metabolism with the majority of the metabolites excreted in bile and less than 1% eliminated in the urine . After dosing of montelukast, the maximum plasma concentration is usually less than 1 µM (Karonen et al., 2010) . The discrepancy in concentrations between the in vitro phenotyping experiments and the in vivo situation raises the possibility that other P450 isoforms could be involved. In addition, an in vivo study using gemfibrozil, whose glucuronide metabolite is a mechanism-based inactivator of CYP2C8, indicated marked inhibition of montelukast in vivo and suggested a previously unknown role for CYP2C8 in montelukast metabolism (Karonen et al., 2010) . More recent data indicates that CYP2C8 plays a role in the in vitro metabolism of montelukast at clinically relevant concentrations (Filppula et al., 2011) . Our second aim was to further evaluate the contribution of CYP2C8 in the metabolism of montelukast in vitro. Given that montelukast demonstrated CYP2C8 selectivity at clinically relevant concentrations, we also characterized montelukast for its potential as an in vitro probe substrate versus the panel of twenty-two known CYP2C8 inhibitors.
The ability to predict changes in the exposure levels of a given drug in the presence of an inhibitor for the in vivo situation is useful (Rostami-Hodjegan and Tucker, DMD # 39065 Foti et al., 2010) . Our final aim was to mine the literature for clinical DDI data and to correlate the DDI sensitivity of six probe substrates (cerivastatin, fluvastatin, montelukast, pioglitazone, repaglinide and rosiglitazone) with known contribution to clearance from CYP2C8. (Gelboin et al., 1995) and a LEAP CTC HTS PAL autosampler equipped with a dual-solvent self-washing system (CTC Analytics, Carrboro, NC). The injection volume was 10 µL for each sample. LC separation was achieved using a Gemini C18 2.0 x 30 mm 5 µm column (Phenomenex, Torrance, CA). Gradient elution (flow rate = 500 µL/minutes) was carried out using a mobile phase system consisting of (A) 5 mM ammonium formate with 0.1% formic acid and (B) acetonitrile with 0.1% formic acid. The solvent flow was diverted from the MS/MS system for the first 20 seconds to remove any non-volatile salts.
Materials and Methods
Materials
MS/MS conditions were optimized for individual analytes, accordingly. Generic MS parameters included the curtain gas (10 arbitrary units), CAD gas (medium), ionspray voltage (4500 V), source temperature (450 °C) and ion source gas 1 and gas 2 (40 arbitrary units, each (1)
In the preceding equations, K m is equal to the substrate concentration at half maximal 
Results
The inhibition constants (K i ) for a set of twenty-two effectors were determined for the probe substrates amodiaquine, montelukast, paclitaxel, repaglinide and rosiglitazone in vitro (Table 1 , structures in Figure 1 ). Competitive inhibition profiles were observed in all cases.
Repaglinide was the most sensitive probe substrate, followed by amodiaquine, rosiglitazone, and montelukast, while paclitaxel exhibited marked differences in observed inhibition potency from the other probe substrates. In addition to the set of competitive inhibition constants (K i ), inactivation kinetic constants (K I and k inact )
for gemfibrozil-1-O-β-glucoronide, a mechanism-based inhibitor of CYP2C8, were determined for the five probe substrates. There was a range of values observed among the five probe substrates, with the K I ranging from 10 to 49 µM and the k inact ranging from 0.02 to 0.08 minutes -1 (Table 2 ). The magnitude of in vivo DDI caused by gemfibrozil-1-O-β-glucoronide was predicted for the clinically relevant probe substrates pioglitazone, repaglinide, rosiglitazone and montelukast (Table 2 ).
In pooled human liver microsomes, the oxidation of montelukast resulted in the formation of three major metabolites (M2, M5 and M6; Figure 2 ). Michaelis-Menten kinetic parameters (K m and V max ) were determined for the oxidative metabolism of montelukast over a concentration range of 0-0.25 µM in HLMs and CYP2C8, CYP3A4
and CYP2C9 Supersomes™ (Figure 3 ). Over the range of concentrations formation of M6 (36-hydroxylation) was linear in both CYP2C9 and CYP3A4 Supersomes™. In
CYP2C8 Supersomes™ and HLMs the formation of M6 (36-hydroxylation) followed
Michael-Menten kinetics and the K m was determined to be 14 nM and 65 nM, respectively. A panel of nine P450 enzymes (Supersomes™) was incubated with montelukast ( Figure 4A-4C ). The formation of M2 (sulfoxidation) and M5 (21-hydroxylation) were inhibited with the CYP3A inhibitor ketoconazole (500 nM) plus a CYP3A selective antibody, a combination known to produce a more complete and The metabolism of cerivastatin, fluvastatin, montelukast, pioglitazone, repaglinide and rosiglitazone is partially mediated by CYP2C8 in vivo. In vivo DDI results for those compounds were collected from the literature and compiled (Table 3) . A linear correlation analysis was carried out on the non-transformed data relative to repaglinide; the CYP2C8 probe substrate with the largest number of comparative DDI studies. All probe substrates exhibited lower sensitivity relative to repaglinide. Of currently prescribed probe substrates, the rank in order of decreasing sensitivity was montelukast, pioglitazone, rosiglitazone and fluvastatin.
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Discussion
Drug-drug interactions are one of the primary causes of serious adverse events occurring in clinical practice (Huang et al., 2007) . A crucial part of the drug discovery and development paradigm is screening for and predicting the magnitude of P450-mediated DDIs. Examples of drugs withdrawn from the market due to drug interactions include mibefradil (Po and Zhang, 1998) and cerivastatin (Davidson, 2002) . Cerivastatin was withdrawn from the market after 500 adverse events; almost half of the events were directly correlated with co-administration of the CYP2C8 inhibitor gemfibrozil (Farmer, 2001; Backman et al., 2002) .
In vitro inhibition studies serve as a basis for in vivo DDI predictions. Probe substrate-dependent inhibition has been demonstrated for CYP2C9 (Kumar et al., 2006) , CYP2C19 (Foti and Wahlstrom, 2008) and CYP3A4 (Kenworthy et al., 1999; Stresser et al., 2000; Foti et al., 2010) and may confound predictions of the in vivo situation.
Selection of a probe substrate that is applicable to both the in vitro and in vivo situations may reduce the impact of probe substrate-dependent inhibition on prediction accuracy.
Therefore, a comprehensive understanding of in vitro and in vivo applicability and sensitivity enables appropriate probe substrate selection.
Our selection of in vitro probe substrates was based upon recommendations from the FDA guidance and the availability of clinical DDI data. Amodiaquine, paclitaxel and rosiglitazone have been used as CYP2C8 in vitro probe substrates (Walsky et al., 2005) . Repaglinide was selected due to the availability of clinical DDI results (Huang et al., 2007) , whereas montelukast was selected based on a recent report of CYP2C8-mediated metabolism in vivo (Karonen et al., 2010) . Repaglinide exhibited the greatest sensitivity as an in vitro probe. Relative to repaglinide, a 3-fold average decrease in inhibition potency was observed for rosiglitazone and amodiaquine and a 4-fold decrease for montelukast. Paclitaxel displayed a 15-fold average decrease in observed Plausible mechanisms for probe substrate-dependent inhibition observed in vitro include the presence of multiple binding regions within the P450 active site, metabolic switching and the involvement of more than one enzyme in metabolite formation (Kenworthy et al., 1999; Regal et al., 2005) . The elucidation of the crystal structure of CYP2C8 has provided useful information on how ligands interact with this enzyme and how CYP2C members determine probe substrate specificity. In the ligand-free structure of CYP2C8, the large active site cavity exhibits architecture that approximates a T or Y shape with branches of differing lengths, widths and chemical properties Schoch et al., 2008) . The crystal structures of CYP2C8 with felodipine, montelukast or troglitazone bound demonstrate distinct binding interactions to the CYP2C8 active site: montelukast fills the entire structure of CYP2C8, felodipine occupies the active site cavity near the heme and troglitazone fills the upper portion of the active site, indicating that the probe substrates occupy distinct, although potentially overlapping, binding regions within the active site (Schoch et al., 2008) . Paclitaxel produces two metabolites, 6α-hydroxylpaclitaxel (CYP2C8) and p-3'-hydroxypaclitaxel (CYP3A4), such that metabolic switching is another plausible explanation for the distinctive decrease in sensitivity to inhibition. However, formation of p-3'-hydroxypaclitaxel did not increase upon addition of the inhibitors, indicating that metabolic switching did not occur (data not shown). Additionally, the formation of 6α-hydroxylpaclitaxel was demonstrated to be selective for CYP2C8 (Rahman et al., 1994) .
When taken together, the CYP2C8 results suggest that specific probe substrate-P450 active site interactions may have a marked affect on enzyme inhibition and distinguish between probe substrates that share some overlap in binding modes. The probe substrate montelukast is a leukotriene-receptor antagonist and a known inhibitor of CYP2C8. Although montelukast is a potent and selective inhibitor of CYP2C8 in vitro (Walsky et al., 2005) , it does not alter the clearance of pioglitazone or repaglinide in vivo (Jaakkola et al., 2006; Kajosaari et al., 2006) . More recently, gemfibrozil was shown to markedly increase the plasma concentrations of montelukast, implying that CYP2C8 may contribute to the elimination of montelukast (Karonen et al., 2010) . Experiments were carried out to further evaluate which P450 enzymes were responsible the in vitro metabolism of montelukast. Three P450-mediated metabolites of montelukast are M2 (sulfoxdation), M5 (21-hydroxylation) and M6 (36-hydroxylation) as shown in Figure 2 .
According to prescribing information and in vitro studies, CYP3A4 and CYP2C9
are the main P450 enzymes involved in the formation of M2 (sulfoxdation)/M5 (21-hydroxylation) and M6 (36-hydroxylation), respectively. However, at the time of the montelukast phenotyping experiments the in vitro tools to evaluate CYP2C8 were lacking. More so, the high montelukast concentrations (100-500 µM) used in the experiments (100 to 1,000-fold higher than therapeutic total plasma concentrations)
would have saturated the CYP2C8-mediated metabolism and confounded the results.
More recently, in vivo administration of gemfibrozil greatly impaired the elimination of M6 (Karonen et al., 2010) . In addition, CYP2C8 has been shown to be crucial in the in vitro metabolism of montelukast at clinically relevant concentrations (Filppula et al., 2011) . µM), the formation of M6 was predominantly mediated by CYP2C8, not CYP2C9 or CYP3A4 (Figure 4 ). In contrast, administration of gemfibrozil did not reduce the formation of M5 (21-hydroxylation), in agreement that CYP3A4 is responsible for its formation . Together, these results indicate that at clinically relevant concentrations, metabolism by CYP2C8 is a major determinant in the elimination of montelukast.
The mechanism of CYP2C8 inactivation by gemfibrozil-1-O-β-glucoronide is the formation of a benzyl radical intermediate that binds to the γ -meso position of the prosthetic heme and renders CYP2C8 catalytically inactive (Baer et al., 2007) . The inactivation kinetic parameters (K I and k inact ) across five probe substrates (Table 2) were determined. As expected for mechanisms that inactivate through heme modification, the kinetic inactivation parameters between probe substrates were similar. These differences observed also did not play a role in changing the in vivo predictions, as a key characteristic impacting DDI predictions is the fraction metabolized by the specific P450 (f mCYP ) enzyme. Predictions for inhibition by gemfibrozil-1-O-β-glucoronide were driven by the f mCYP2C8 (Hinton et al., 2008) and were insensitive to substrates with f mCYP2C8 values less than 0.65. Using our in vitro kinetic parameters for inactivation by gemfibrozil-1-O-β-glucoronide (Table 2 ) and the f mCYP2C8 of montelukast (0.81), our prediction AUC I /AUC was within 10% of the observed value. Collectively, the P450-phenotyping and DDI predictions indicate that CYP2C8 is the primary enzyme involved in the oxidation of montelukast at clinically relevant substrate concentrations.
The in vivo sensitivity of the CYP2C8 probe substrates may influence selection of CYP2C8 probe substrate for a clinical study. Retrospective analysis of clinical DDI studies from the literature has been used to correlate the relative sensitivity of probe substrates in vivo based upon results from multiple CYP3A4 inhibitors (RagueneauMajlessi et al., 2007; Foti et al., 2010) . repaglinide and a known contribution of CYP2C8 to clearance were our selection criteria for inclusion in the in vivo correlation analysis. The DDI results were averaged for instances where multiple clinical studies for the same inhibitor and probe substrate combination were available and carried out using similar conditions. All of the probe substrates displayed reduced sensitivity relative to repaglinide. Although cerivastatin and repaglinide were sensitive to inhibition by gemfibrozil in vivo, both are substrates of OATP1B1; observed DDI in vivo may be due to a combination of metabolism and transporter inhibition (Hinton et al., 2008) . Gemfibrozil-1-O-β-glucoronide, a key component for the in vivo sensitivity analysis presented here, is an inhibitor of both CYP2C8 and OATP1B1 (Shitara et al., 2004 (Muck et al., 1997; Hatorp and Thomsen, 2000) d (Spence et al., 1995; Backman et al., 2002; Niemi et al., 2003a; Niemi et al., 2003b; Niemi et al., 2004a; Deng et al., 2005; Jaakkola et al., 2005; Tornio et al., 2008a; Karonen et al., 2010 ) e (Kivisto et al., 1998; Mazzu et al., 2000; Niemi et al., 2003b; Jaakkola et al., 2005) f (Jaakkola et al., 2006; Kajosaari et al., 2006; Kim et al., 2007) g (Kajosaari et al., 2006) h (Niemi et al., 2004a; Niemi et al., 2004b; Hruska et al., 2005; Tornio et al., 2008b) 
